When Should You Use a Standard LNP vs. a Custom Lipid/Polymer Formulation?

Lipid nanoparticles (LNPs) have emerged as the gold standard for the delivery of genetic payloads, including mRNA and siRNA. However, the success of a therapeutic program often hinges on the initial selection of the lipid delivery system. For developers, the central question is whether to leverage clinically-validated standard LNP formulations or to invest in lesser known custom formulations.

The decision-making process typically involves a multi-factorial analysis of developmental stage, budgetary constraints, and specific therapeutic targets.

When to Utilize Standard LNP Formulations

Standard formulations—such as SM-102, ALC-0315, DLin-MC3-DMA, or LP-01—are frequently the preferred choice for early-stage R&D and proof-of-concept studies.

• Accelerated Timelines: Utilizing off-the-shelf components allows for immediate benchtop testing without the lead times associated with synthesis and characterization.

• Benchmarking: Standard lipids provide a reliable baseline against which new technologies can be measured.

• Reduced Risk: Many of these lipids have extensive literature and safety profiles, providing a clear regulatory pathway for certain applications.

  
  

What Are Custom Lipid or Polymer Formulations?

Custom nanoparticle formulations are tailor-made formulations designed to meet unique project requirements. These systems involve designing or selecting lipids or polymers that:

• Target specific organs or cell types beyond the liver.

• Improve nanoparticle stability at room temperature or under stress.

• Reduce immunogenicity or toxicity.

• Lower manufacturing costs by avoiding patented lipids.

• Enhance encapsulation efficiency for particular nucleic acids or drugs.

  
  

Developing a custom formulation requires expertise in lipid chemistry, formulation science, and preclinical testing. It often involves iterative optimization to balance delivery efficiency, safety, and manufacturability.

When to Choose a Custom Formulation

Consider a custom formulation if:

• You want to avoid high licensing fees associated with standard LNPs.

• Your therapeutic target is outside the liver or spleen, such as the lungs, brain, or tumors.

• You need better stability for storage and transport, especially in resource-limited settings.

• Your API has unique properties requiring specialized encapsulation.

• You aim to differentiate your product with proprietary delivery technology.

  
  

For example, a company developing an mRNA therapy for lung disease might design a lipid system that enhances lung targeting and retention. This approach can improve therapeutic outcomes and reduce off-target effects.

Balancing Cost, Time, and Performance

Decision Matrix: A Comparative Overview

Feature	Standard Formulations	Custom Formulations
Primary Use Case	R&D / Benchmarking	Clinical Leads / Targeted Therapy
IP Accessibility	Public / Licensing Required	Proprietary Ownership/More Cost Effective Licensing
Development Cost	Moderate	High (Initial Investment)
Regulatory Path	Well-documented	May Require Novel Pathways

Choosing between standard and custom formulations involves trade-offs:

Early-stage projects often benefit from standard LNPs to generate data quickly. Later-stage or specialized projects may justify the investment in custom formulations to meet specific needs.

Practical Steps to Decide

1. Define your therapeutic goals: What tissue do you need to target? What is your API’s nature?

2. Assess your budget and timeline: Can you afford licensing fees? How fast do you need results?

3. Review existing data: Are there published studies using standard LNPs with similar APIs?

4. Consult formulation experts: Discuss feasibility and risks of custom lipid development.

5. Plan for scale-up: Consider manufacturing complexity and regulatory pathways.

   
   

Potential Examples

• Early-stage mRNA vaccine development: Researchers used DLin-MC3-DMA LNPs to quickly test vaccine candidates in mice. This approach provided clear efficacy data within months, helping secure funding.

• Targeted siRNA therapy for cancer: A biotech company developed a custom formulation that included a targeting ligand to deliver siRNA specifically to tumor cells. This improved therapeutic index and reduced side effects.

• Stable mRNA formulation for tropical regions: A team designed a custom formulation with enhanced thermal stability, allowing vaccine storage at higher temperatures, reducing cold-chain dependency.

Reach out to our experts here at Helix Biotech, Inc. to help you decide your best path forward.

Contact us here.